Your browser doesn't support javascript.
loading
Is Helicobacter pylori Associated Functional Dyspepsia Correlated With Dysbiosis?
Kim, Yeon-Ji; Chung, Woo Chul; Kim, Byung Wook; Kim, Sung Soo; Kim, Jin Il; Kim, Na Jin; Yoo, Jinho; Kim, Soo Hwan.
Afiliación
  • Kim YJ; Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.
  • Chung WC; Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.
  • Kim BW; Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.
  • Kim SS; Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.
  • Kim JI; Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea.
  • Kim NJ; Medical Library, The Catholic University of Korea, Seoul, Korea.
  • Yoo J; Bio-age, Medical Development Institute, Seoul, Korea.
  • Kim SH; Bio-age, Medical Development Institute, Seoul, Korea.
J Neurogastroenterol Motil ; 23(4): 504-516, 2017 Oct 30.
Article en En | MEDLINE | ID: mdl-28992674
ABSTRACT
BACKGROUND/

AIMS:

To assess the long-term effect of Helicobacter pylori eradication on symptomatic improvement according to the type of antibiotic and the duration of treatment in H. pylori-associated functional dyspepsia.

METHODS:

We searched Pubmed, Embase, CINAHL, and the Cochrane library databases for randomized controlled trials written in English and undertaken up to August 2016 that met our eligibility criteria. The search methodology used combinations of the following keywords Helicobacter pylori OR H. pylori OR HP; dyspepsia OR functional dyspepsia OR non-ulcer dyspepsia; eradication OR cure OR treatment. The study outcome was the summary odds ratio (OR) for symptomatic improvement in H. pylori-associated functional dyspepsia with successful eradication therapy. Subgroup analyses were performed based on the type of antibiotic, and the duration of treatment, whether or not patients had symptoms of irritable bowel syndrome, and on race.

RESULTS:

Sixteen randomized controlled trials met the inclusion criteria. The summary OR for symptomatic improvement in patients in our eradication group was 1.33 (95% confidence interval [CI], 1.16-1.54; P < 0.01). In a subgroup analysis on type of antibiotic, symptomatic improvement with metronidazole-containing regimen (OR, 1.87; 95% CI, 1.26-2.77) was better than treatment with clarithromycin (OR, 1.29; 95% CI, 1.11-1.50). H. pylori eradication therapy given for 10-14 days was the more effective for symptom improvement than 7-day therapy. When the studies excluding irritable bowel syndrome cases were analyzed, there were no therapeutic effects of H. pylori eradication on symptomatic improvement.

CONCLUSIONS:

In the clinical setting, the most effective H. pylori eradication regimen for functional dyspepsia to provide relief of symptoms is a metronidazole-based treatment regimen for at least 10 days. The explanation for this is that H. pylori-associated functional dyspepsia could be associated with dysbiosis.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Risk_factors_studies / Systematic_reviews Idioma: En Revista: J Neurogastroenterol Motil Año: 2017 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Risk_factors_studies / Systematic_reviews Idioma: En Revista: J Neurogastroenterol Motil Año: 2017 Tipo del documento: Article